BAX Stock Chart & Stats
$454.05
$0.00(0.00%)
At close: 4:00 PM EDT
$454.05
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$286.31 - $498.79
Previous CloseN/A
Volume0.00
Average Volume (3M)53.00
Market Cap
$219.66B
Enterprise Value$17.72K
Total Cash (Recent Filing)$2.15B
Total Debt (Recent Filing)$9.67B
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Oct 29, 2026EPS Estimate
9.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding516,996,000
10 Day Avg. Volume0
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$468.67Price Target Upside3.22% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)34.71
Revenue Forecast (FY)$197.41B
Bulls Say, Bears Say
Bulls Say
Recurring Healthcare DemandBaxter’s product mix includes consumables, IV solutions, dialysate and single-use treatment sets that are replenished as patient care continues. This recurring-use model can support revenue resilience across hospital and dialysis settings and reduces reliance on occasional capital-equipment purchases.
Broad-based Revenue GrowthGrowth across every segment and geography indicates that Baxter’s recent performance is not dependent on one isolated business or market. Broad-based expansion improves the durability of the revenue trend, supports operating scale and provides a stronger foundation for continued investment in products and execution.
Advanced Surgery And Drug Compounding MomentumStrong growth in Advanced Surgery and Drug Compounding demonstrates traction in important clinical product categories and helps diversify Baxter’s portfolio. Continued adoption in these businesses could strengthen mix, support future revenue growth and partially offset weaker areas within the company.
Bears Say
Persistent UnprofitabilityNegative EBIT, net income and return on equity show that Baxter’s revenue base is not currently translating into profitable returns. Persistent losses reduce internally generated capital, limit financial flexibility and make sustained margin recovery essential to improving the company’s fundamental profile.
Elevated LeverageAlthough leverage has improved from its 2022 peak, Baxter remains meaningfully geared relative to its equity base. Debt obligations can constrain capital allocation and increase sensitivity to operating weakness, making debt reduction and reliable cash generation important to restoring balance-sheet resilience.
Margin And Product Execution PressureLower gross and operating margins point to pressure from manufacturing costs, absorption and tariffs, while the Novum IQ LVP shipment hold adds product execution risk in Infusion Systems. Together, these issues can weigh on earnings quality and delay the recovery in sustainable profitability.
Baxter International News
BAX FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest stock price was $286.31 and its highest was $498.79 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is $219.66B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Oct 29, 2026 which is in 27 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Jul 30, 2026. The company reported $10.133 earnings per share for the quarter, beating the consensus estimate of $6.641 by $3.492.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International does not currently pay dividends.
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 9.39.
How many shares outstanding does Baxter International have?
Baxter International has 516,996,000 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of $10.133 in its last earnings report, beating expectations of $6.641. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in MX:BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$468.67 (3.22% Upside)
$468.67 (3.22% Upside)
Blogger Sentiment
Neutral
MX:BAX Sentiment 57%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.60%
12-Months-Change
Fundamentals
Return on Equity
0.16%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Baxter International
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a mostly positive picture: revenue growth was broad-based with Q2 organic sales up 5%, management raised full-year sales and EPS guidance, free cash flow and balance sheet metrics improved, and several product and operational initiatives showed traction (Baxter GPS, PeerVue, Connex 360, Dynamo). However, meaningful near-term headwinds remain — margin pressure from higher-cost inventory and tariffs, ongoing supply constraints (notably in injectables), and the disruption around the Novum IQ LVP platform. The tariff refund was a helpful one-time boost but is nonrecurring. On balance, the company demonstrated tangible operational progress and raised guidance while acknowledging discrete challenges that are being managed.View all MX:BAX earnings summariesBAX Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
BAX Stock 12 Month Forecast
Average Price Target
$468.67
▲(3.22% Upside)